Novartis reported today that a clinical trial of the drug, known as canakinumab, when combined with chemotherapy agent, docetaxel, failed to extend the lives of patients with advanced or metastatic non-small cell lung cancer compared to just chemotherapy...
The temporary medicines unit built for the agency's Central Intravenous Additive Service can produce up to 2,600 syringes weekly to meet growing demand
The development technology firm plans to use the funds, sourced from a wide range of investors, to expand its dev-ops platform and expand its global reach.
Valneva and Pfizer have initiated a Phase 2 study for their Lyme disease vaccine candidate: which is the only active Lyme disease vaccine in clinical development today.
The CRO will receive funding to fuel a five-year Research Project Award, with the goal to design and conduct research of potential PTSD treatment options.
The companies announcing acquisitions, new hires, promotions and other news this month include Syneos, Elligo, PCI Pharma Services, I Holland and more.
The 2020 Pfizer/BioNTech COVID-19 vaccine trial recruited more than 44,000 participants and reached submission for emergency authorization in 248 days: showing unprecedented speed and agility in the context of a global pandemic. So what have been the...
The Verisense Pulse+ can measure heart rate, oxygen saturation, emotional responses, and activity and sleep levels of at-home clinical trial participants.
A leader from the genetic solutions firm explains how genetic testing and counseling can help trial teams form more beneficial connections with patients.
The company has increased capabilities at its Bend, Oregon location, including its SimpliFiH Solutions first-in-human services for small-molecule drugs.
The partnership reportedly will center on optimizing integration for EHR data and remote-source data review to help accelerate clinical research results.
An executive from the rare disease technology solutions company discusses how forcing connections with patients can boost research into such conditions.
A leader from the risk-based quality management solutions provider will discuss the growing interest in the technology, during this year’s SCOPE event.
An executive from the clinical trial technology provider will share how direct data capture can save time, avoid errors and improve the patient experience.
The annual event, moved to the virtual realm thanks to COVID-19, offers content on remote monitoring, drug development technology and other key topics.
The collaboration will leverage patients’ biological and medical data to streamline patient identification and recruitment efforts in clinical research.
The US Food and Drug Administration (FDA) has issued guidance for companies developing vaccines, diagnostics and therapeutics against new variants of SARS-CoV-2.
A senior clinical research associate from the CRO discusses how the pandemic has touched her workday, and how she is dealing with the myriad challenges.
The technology is designed to streamline and simplify integration, data collection and analysis, and digital biomarker discovery with wearable sensors.
The on-pack technology enables consumers, retailers and others to harness mobile devices in order to verify the authenticity of pharmaceutical products.
The two companies will work to advance precision cancer medicine by harnessing genomics data in trial design, recruitment, site selection and other areas
With demand for fast-tracking therapies, vaccines and other products increasing, companies like Azzur Group offer the ability to add capabilities quickly.
Quotient Sciences, a drug development and manufacturing accelerator with facilities in the UK and the US, has acquired Arcinova, a UK-based multiservice contract development and manufacturing organization (CDMO).
A leader from the clinical data solutions firm explains how the challenges created by the pandemic have helped fuel creativity and innovation in studies.
In the drive to advance personalized medicine, researchers are increasingly turning to radiomics to assist in the discovery of new types of biomarkers.
A study by two trial technology firms reportedly indicates that decentralized trials are outperforming on-site in recruitment, retention and other aspects.
The American Heart Association’s Heart of Communicating Science modules are designed to help experts break complex talk into easy-to-understand language.
Immunai has secured a total of $80m in funding to develop and promote its efforts to harness machine learning to fuel advancement of novel immunotherapies.
The global professional services firm has signed on the newest partner in the collaboration, aimed toward promoting innovation in pharma manufacturing.
The federal agency continues to keep researchers, pharma firms and citizens apprised of current happenings and research related to the virus and pandemic.
According to a company leader, electronic clinical outcome assessment solutions should take ease of use for patients, sponsors and others into account.
William Gholston, with the Tampa Bay Buccaneers football team, is donating to the Moffitt Cancer Center to fund research into cancer treatment disparities.
The founder of Andaman7’s leukemia diagnosis, and his son’s experience with bone cancer, have helped inform the firm's tech and patient-centric approach.
